Keld Fosgerau is a seasoned drug development professional with over 25 years of international experience, currently serving as the CEO and founder of Fosgerau Consult ApS. His extensive background spans various sectors within the life sciences industry, including virtual start-ups, established biotech firms, contract research...
Keld Fosgerau is a seasoned drug development professional with over 25 years of international experience, currently serving as the CEO and founder of Fosgerau Consult ApS. His extensive background spans various sectors within the life sciences industry, including virtual start-ups, established biotech firms, contract research organizations (CROs), and large integrated pharmaceutical companies. Keld's expertise lies in leading cross-functional teams and managing complex projects, with a particular focus on research initiatives that range from novel target discovery to early clinical development.
At Fosgerau Consult ApS, Keld is dedicated to advancing innovative therapeutic solutions, particularly in the realm of peptide-based drugs. One of his key projects includes his involvement with Pephexia Therapeutics, a biotech company that is pioneering the development of treatments for cancer cachexia. This initiative has successfully raised over 25 million DKK in funding, underscoring the project's potential impact on patient care and quality of life. Keld's commitment to addressing unmet medical needs is reflected in his strategic approach to drug discovery and clinical development, leveraging his deep understanding of metabolism, protein chemistry, and animal models.
Keld's leadership is characterized by a strong track record of delivering results in drug development, with a particular emphasis on Type 2 diabetes and other metabolic disorders. His ability to navigate the complexities of CRO management and foster collaboration across diverse teams has positioned him as a respected figure in the industry. Through his work at Fosgerau Consult ApS and Pephexia Therapeutics, Keld Fosgerau continues to drive innovation and contribute to the advancement of life-saving therapies in the biotech landscape.
